Aptiv Solutions Launches ADDPLAN DF 3.0

May 14, 2014
By Applied Clinical Trials Editors

ICON announced that Aptiv Solutions, an ICON company for the design and implementation of adaptive trials, has released ADDPLAN DF 3.0, which incorporates complex statistical methodologies to prevent under and over-estimation of a therapeutic’s maximum target dose (MTD) during Phase I dose escalation trials. Accurate estimation of MTD can minimize safety and efficacy issues leading to late phase clinical trial failures.

Read the full release here.

lorem ipsum